Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2021

Revenue From Contract With Customer [Abstract]

Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer

The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer.

	For the Three Months Ended March 31, 2021
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform		Commercial Platform		Consolidated Total
United States	$	20,157	$	5,229	$	13,259	$	38,645
China		8		197		—		205
Other foreign countries		500		1,675		—		2,175
Total revenue	$	20,665	$	7,101	$	13,259	$	41,025

	For the Three Months Ended March 31, 2020
	(In Thousands)
	Oncology Innovation Platform		Global Supply Chain Platform		Commercial Platform		Consolidated Total
China	$	28,308	$	205	$	—	$	28,513
United States		—		1,980		15,542		17,522
Other foreign countries		79		821		—		900
Total revenue	$	28,387	$	3,006	$	15,542	$	46,935

Summary of Receivables and Contract Liabilities From Contracts with Customers

The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers.

	March 31, 2021			December 31, 2020
	(In Thousands)
Accounts receivable, gross	$	46,935		$	45,792
Chargebacks and other deductions		(17,264	)		(12,552	)
Provision for credit losses		(9,482	)		(9,637	)
Accounts receivable, net	$	20,189		$	23,603
Deferred revenue		1,289			1,147
Total contract liabilities	$	1,289		$	1,147

Summary of Accounts Receivable and Contract Assets Balances by Reportable Segments

The following tables illustrate accounts receivable and contract asset balances by reportable segments.

	March 31, 2021
	(In Thousands)
	Oncology Innovation Platform			Global Supply Chain Platform			Commercial Platform			Consolidated Total
Accounts receivable, gross	$	9,167		$	3,589		$	34,179		$	46,935
Chargebacks and other deductions		—			—			(17,264	)		(17,264	)
Provision for credit losses		(8,919	)		(138	)		(425	)		(9,482	)
Accounts receivable, net		248			3,451			16,490			20,189

	December 31, 2020
	(In Thousands)
	Oncology Innovation Platform			Global Supply Chain Platform			Commercial Platform			Consolidated Total
Accounts receivable, gross	$	10,783		$	4,074		$	30,935		$	45,792
Chargebacks and other deductions		—			(1	)		(12,551	)		(12,552	)
Provision for credit losses		(8,919	)		(164	)		(554	)		(9,637	)
Accounts receivable, net	$	1,864		$	3,909		$	17,830		$	23,603